CRISPR/Cas9 technology generated a G to C change resulting in a tryptophan to cysteine substitution at amino acid 160 (p.W160C). This corresponds to a congenital insensitivity to pain-causing variant identified in human. (J:312689)
查看原文 参与反馈
CRISPR/Cas9 technology generated a G to C change resulting in a tryptophan to cysteine substitution at amino acid 160 (p.W160C). This corresponds to a congenital insensitivity to pain-causing variant identified in human. (J:312689)